Sustained Virologic Response Following a Shortened Course of Direct-Acting Antiviral Therapy in an HIV/HCV Co-Infected Patient With Previous Treatment Experience: A Case Report.
Natasha Bhutani, Yoona Lee, Maria A Longo et al.
✦ AI-curated · Sources linked
Case in brief
A 47-year-old treatment-experienced man with HIV and chronic HCV had completed 10 weeks of sofosbuvir-velpatasvir before starting sofosbuvir-velpatasvir-voxilaprevir. He took the triple regimen for approximately 4 weeks, then was lost to follow-up for 3 months. HCV testing showed sustained virologic response 12 weeks after treatment (SVR12), despite the shortened course. The report highlights that virologic response was documented after incomplete triple-direct-acting antiviral therapy in this individual.
What made this case unusual
SVR12 followed approximately 4 weeks of triple therapy in a treatment-experienced patient who had already received 10 weeks of sofosbuvir-velpatasvir.
Diagnostic / clinical pearl
For patients lost to follow-up or who did not complete HCV therapy, assess HCV RNA for SVR12 before considering treatment re-initiation.